Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

By Yoon-Koo Kang, W. Kang, D. Shin, J. Chen, J. Xiong, J. Wang, M. Lichinitser, Z. Guan, R. Khasanov, L. Zheng and 5 more. Annals of Oncology, 2009

775 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/25e58085654f7277f8e3b4d5cf5c1477fd6ce426

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Allison O'Hair
2. Dimitris J. Bertsimas
3. John Silberholz
4. Stephen Relyea

Citations in the corpus

• An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer (2016, background): “…studies, including cancer extent, histology, a patient’s history of prior adjuvant therapy and surgery, and further details of patients’ initial conditions, such as their baseline bilirubin levels or body surface areas (Ajani et al. 2010, Bang et al. 2010, Kang et al. 2009, Koizumi et al. 2008).”